Lasa Supergenerics Limited (NSE:LASA)
7.20
+0.21 (3.00%)
Aug 21, 2026, 3:28 PM IST
Lasa Supergenerics Revenue
Lasa Supergenerics had revenue of 13.25M INR in the quarter ending June 30, 2026, a decrease of -93.42%. This brings the company's revenue in the last twelve months to 65.20M, down -95.23% year-over-year. In the fiscal year ending March 31, 2026, Lasa Supergenerics had annual revenue of 253.41M, down -82.82%.
Revenue (ttm)
65.20M
Revenue Growth
-95.23%
P/S Ratio
5.53
Revenue / Employee
987.86K
Employees
66
Market Cap
360.73M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 253.41M | -1.22B | -82.82% |
| Mar 31, 2025 | 1.47B | 430.26M | 41.20% |
| Mar 31, 2024 | 1.04B | -259.96M | -19.93% |
| Mar 31, 2023 | 1.30B | -66.97M | -4.88% |
| Mar 31, 2022 | 1.37B | -652.53M | -32.24% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sigachi Industries | 4.76B |
| Valiant Laboratories | 3.06B |
| Amanta Healthcare | 2.91B |
| Balaxi Pharmaceuticals | 2.80B |
| Bafna Pharmaceuticals | 1.43B |
| Alpa Laboratories | 1.11B |
| Par Drugs and Chemicals | 1.09B |
| Vaishali Pharma | 1.08B |